Prevalence of chronic obstructive pulmonary disease (COPD) and the disease's burden varies significantly by state.

Theravance Biopharma’s partner Viatris has received China's National Medical Products Administration (NMPA) approval for ...

COPD has a large economic impact on the healthcare system and a destructive impact on the lives of patients and their ...

In those cases, each standard deviation increase in VMR was tied to a 50% higher likelihood of experiencing a major adverse ...

Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.

A quarter of people seeking care for symptoms of chronic respiratory diseases in Kenya may incur "catastrophic" health costs, ...

According to a new comprehensive report from The Insight Partners, the global pulmonary drug delivery system market is ...

Theravance Biopharma announces Viatris receives China NMPA approval for Yupelri inhalation solution to treat COPD: Dublin Friday, June 27, 2025, 17:00 Hrs [IST] Theravance Biophar ...

Between 14 days and 1 day out from an acute exacerbation of COPD, a digital inhaler measured significant drops in inhalation ...

Researchers discover an unusual accumulation of particles in people with the disease; the causes are still unclear.

Chronic obstructive pulmonary disease (COPD) affects 25 million people in the U.S. and is the fifth leading cause of death ...

Researchers looked at lung tissue from 28 COPD patients and 15 smokers who underwent surgery for suspected or confirmed lung ...